Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma

The exonic single‐nucleotide variant rs11762213 located in the MET oncogene has recently been identified as a prognostic marker in clear cell renal cell carcinoma (ccRCC). This finding was validated with The Cancer Genome Atlas (TCGA) cohort, and the biologic implications were explored.

[1]  X. Liu,et al.  Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival , 2014, Clinical Cancer Research.

[2]  Amit Verma,et al.  Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development , 2013, Genome Biology.

[3]  T. Choueiri,et al.  Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma , 2013, Cancer journal.

[4]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[6]  Han Liu,et al.  Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. , 2013, European urology.

[7]  Kathleen F. Kerr,et al.  Testing for improvement in prediction model performance , 2013, Statistics in medicine.

[8]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[9]  G. Gibney,et al.  c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. , 2013 .

[10]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Raymond K. Auerbach,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[12]  R. Klein,et al.  A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival , 2012, Clinical Cancer Research.

[13]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[14]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[15]  T. Choueiri,et al.  Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[17]  K. Suszták,et al.  Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.

[18]  P. Kantoff,et al.  Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality , 2011, Cancer Prevention Research.

[19]  W. Linehan,et al.  Impact of Genetics on the Diagnosis and Treatment of Renal Cancer , 2011, Current urology reports.

[20]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[21]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[22]  Christopher A. Haiman,et al.  The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer , 2009, Nature Genetics.

[23]  A. C. Pereira,et al.  Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. , 2007, Cancer research.

[24]  Y. Chrétien,et al.  Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients , 2006, Cancer.

[25]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[26]  F. Guillé,et al.  Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy , 2005, Cancer.

[27]  O. Volpert,et al.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[29]  A. Brookes.  The essence of SNPs. , 1999, Gene.

[30]  P. Comoglio,et al.  Overexpression of the met/HGF receptor in renal cell carcinomas , 1996, International journal of cancer.

[31]  Michael B Atkins,et al.  Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. , 2013, The Lancet. Oncology.